LNTH vs TARS
Lantheus Holdings vs Tarsus Pharmaceuticals, Inc. — AI-powered side-by-side comparison
LNTH
Lantheus Holdings
67
Buy
VS
TARS
Tarsus Pharmaceuticals, Inc.
63
Buy
| Metric | LNTH | TARS |
|---|
| AI Score |
67
|
63
|
| Price |
$100.63
|
$69.50
|
| P/E Ratio |
23.91×
|
-63.72×
|
| ROE |
21.4%
|
-19.3%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
60.1%
|
90.6%
|
| Debt / Equity |
0.44×
|
0.26×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
42.5
|
80.7
|
| Beta |
-0.057
|
0.512
|
| Expected Upside |
+7.8%
|
—
|
AI Committee View
Current Innellis committee reasoning for LNTH versus TARS.
LNTH leads by 4 points.
LNTH scores 67/100 (Buy) versus TARS at 63/100 (Buy).
LNTH Committee View
50% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- 3 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- MACD histogram negative -- bearish momentum — Technical
TARS Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Revenue growing 105.2% YoY -- genuine top-line momentum — Growth
- MACD histogram positive -- bullish momentum — Technical
- Low leverage (debt-to-equity 0.21) -- balance sheet can absorb a shock — Risk
Bear Case
- Price-to-book of 10.1x prices in significant intangible value — Value
- ROE of only -13.5% -- cheap may mean cheap for a reason — Value
- RSI at 81 is in overbought territory — Technical